Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.

"Declarations Conflict of interestIvo Demel—AstraZeneca (advisory board member); David Belada—AstraZeneca (advisory board member); Martin Čerňan—AstraZeneca (advisory board member); Pavel Jindra—AstraZeneca (advisory board member). Other authors have no competing interests to declare. Conflict of interest Ivo Demel—AstraZeneca (advisory board member); David Belada—AstraZeneca (advisory board member); Martin Čerňan—AstraZeneca (advisory board member); Pavel Jindra—AstraZeneca (advisory board member). Other authors have no competing interests to declare."

"Funding Open access publishing supported by the National Technical Library in Prague. This study was supported by the Ministry of Health, Czech Republic—conceptual development of the research organization (Faculty Hospital of Pilsen – FNPI, 00669806) by grant IGA_LF_2023_005; by the Programme Cooperation, Research Area ONCO; and by MH CZ-DRO (UHHK, 00179906). Petra Rozsívalová was partially supported by a Charles University grant (SVV 260 665)."